Exploring the Relationship between FEV
Administration, Intravenous
Adult
Amikacin
/ administration & dosage
Aminoglycosides
/ administration & dosage
Anti-Bacterial Agents
/ administration & dosage
Area Under Curve
Cystic Fibrosis
/ drug therapy
Dose-Response Relationship, Drug
Female
Forced Expiratory Volume
/ physiology
Gentamicins
/ administration & dosage
Humans
Male
Retrospective Studies
Tobramycin
/ administration & dosage
Young Adult
Bayesian pharmacokinetics
amikacin
cystic fibrosis
gentamicin
pulmonary exacerbations
tobramycin
Journal
Pharmacotherapy
ISSN: 1875-9114
Titre abrégé: Pharmacotherapy
Pays: United States
ID NLM: 8111305
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
05
01
2020
revised:
13
03
2020
accepted:
24
03
2020
pubmed:
8
4
2020
medline:
24
4
2021
entrez:
8
4
2020
Statut:
ppublish
Résumé
Systemic aminoglycosides remain a cornerstone of treatment for cystic fibrosis (CF) pulmonary exacerbations (PEx); however, the impact of aminoglycoside pharmacokinetics (PK) on outcomes is not well defined in adult CF patients. Our objective was to assess the impact of increasing PK exposures on the clinical outcomes of PEx treatment in adult CF patients receiving high-dose and standard-dose extended-interval aminoglycosides. We conducted a retrospective study of adult CF patients treated with an intravenous aminoglycoside for a PEx. Serum amikacin, gentamicin, and tobramycin levels and forced expiratory volume over 1 second (FEV The study included 51 patients who contributed 188 FEV Increasing aminoglycoside AUC
Substances chimiques
Aminoglycosides
0
Anti-Bacterial Agents
0
Gentamicins
0
Amikacin
84319SGC3C
Tobramycin
VZ8RRZ51VK
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
584-591Informations de copyright
© 2020 Pharmacotherapy Publications, Inc.
Références
Heltshe SL, Goss CH, Thompson V, et al. Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis. Thorax 2016;3:223-29.
Sanders DB, Bittner RCL, Rosenfeld M, Redding GJ, Goss CH. Pulmonary exacerbations are associated with subsequent FEV1 decline in both adults and children with cystic fibrosis. Pediatr Pulmonol 2011;4:393-400.
Flume PA, Mogayzel PJ, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009;9:802-8.
Butterfield JM, Lodise TP, Beegle S, Rosen J, Farkas J, Pai MP. Pharmacokinetics and pharmacodynamics of once-daily administration of intravenous tobramycin in adult patients with cystic fibrosis hospitalized for an acute pulmonary exacerbation. Antimicrob Agents Chemother 2013;10:5175-77.
Bland CM, Pai MP, Lodise TP. Reappraisal of contemporary pharmacokinetic and pharmacodynamic principles for informing aminoglycoside dosing. Pharmacotherapy 2018;12:1229-38.
Hamilton KW, Bilker WB, Lautenbach E. Controlling for severity of illness in assessment of the association between antimicrobial-resistant infection and mortality: impact of calculation of Acute Physiology and Chronic Health Evaluation (APACHE) II scores at different time points. Infect Control Hospital Epidemiol 2007;7:832-6.
Thom KA, Shardell MD, Osih RB, et al. Controlling for severity of illness in outcome studies involving infectious diseases: impact of measurement at different time points. Infect Control Hospital Epidemiol 2008;11:1048-53.
Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. Population. Am J Respir Crit Care Med 1999;1:179-87.
Schluchter MD, Konstan MW, Drumm ML, Yankaskas JR, Knowles MR. Classifying severity of cystic fibrosis lung disease using longitudinal pulmonary function data. Am J Respir Crit Care Med 2006;7:780-86.
Morgan WJ, VanDevanter DR, Pasta DJ, et al. Forced expiratory volume in 1 second variability helps identify patients with cystic fibrosis at risk of greater loss of lung function. J Pediatr 2016;116-21.e2.
Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007;2:R31.
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;1:31-41.
Macdonald I, Staatz CE, Jelliffe RW, Thomson AH. Evaluation and comparison of simple multiple model, richer data multiple model, and sequential interacting multiple model (IMM) Bayesian analyses of gentamicin and vancomycin data collected from patients undergoing cardiothoracic surgery. Ther Drug Monit 2008;1:67-74.
Winter ME. Basic clinical pharmacokinetics. Philadelphia: Lippincott Williams & Wilkins; 2003:576.
Pai MP, Russo A, Novelli A, Venditti M, Falcone M. Simplified equations using two concentrations to calculate area under the curve for antimicrobials with concentration-dependent pharmacodynamics: daptomycin as a motivating example. Antimicrob Agents Chemother 2014;6:3162-7.
Dong K, Moon KM, Chen V, et al. Identification of novel blood biomarkers of treatment response in cystic fibrosis pulmonary exacerbations by label-free quantitative proteomics. Sci Rep 2019;1:17126.
Smith PF, Ballow CH, Booker BM, Forrest A, Schentag JJ. Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients. Clin Ther 2001;8:1231-44.